Targovax ASA   Report issue

For profit Phase 1 Phase 2
Founded: Helsinki Finland (2009)
Status: Left NME R&D (2022)

Organization Overview

First Clinical Trial
2012
NCT01598129
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Oncos Therapeutics Ltd. | Targovax ASA | Targovax Oy

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Appendiceal Neoplasms (Phase 2)

Colorectal Neoplasms (Phase 1)

Melanoma (Phase 1)

Mesothelioma (Phase 2)

Pancreatic Neoplasms (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 10
  • # of Trial APIs: 13